UnitedHealth Group CEO Andrew Witty, during the company’s first earnings call since the death of executive Brian Thompson, criticized the U.S. healthcare system’s complexity and high costs, driven by a profit-focused model where high costs benefit many participants. Witty specifically cited discrepancies in drug pricing, blaming pharmaceutical companies while asserting UnitedHealth’s efforts to improve transparency. Despite record 2024 revenues, the company reported worse-than-expected quarterly results, and Witty reaffirmed the company’s commitment to improving the system.
Read More
The situation is truly disheartening: a medical student, facing a potentially life-threatening condition, is having her crucial medication denied by her insurance company. She reports that despite numerous attempts to get authorization, including submitting extensive documentation and appeals, the insurer, Blue Cross and Blue Shield of Kansas City, remains steadfast in its refusal to cover the medication, Promacta (Eltrombopag), for her immune thrombocytopenia.
This isn’t an isolated incident; many people share similar experiences with insurance companies putting profits over patients’ well-being. Stories abound of individuals forced into repeated emergency room visits for necessary treatments simply because their insurance company won’t cover the medication from an out-of-state pharmacy or insists on generic alternatives despite documented ineffectiveness or harmful side effects.… Continue reading
The recent killing of UnitedHealthcare’s CEO highlights widespread public anger over soaring healthcare costs, the leading cause of bankruptcy in the U.S. Despite efforts like the Affordable Care Act and Inflation Reduction Act to expand coverage and lower prices, healthcare remains unaffordable, forcing many to forgo necessary care. The U.S. system’s fragmented nature, coupled with rising premiums and industry consolidation, exacerbates the problem. Ongoing initiatives like drug price negotiations and antitrust actions offer potential solutions, but significant reform is needed to address the systemic issues driving high costs.
Read More
John Q. Hosedrinker 
Matt Underwood